EUVIMEDEUVIMED entdecken
Open Access

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant

Elena Martinelli, Juntao Ke, Atlas Khan, Janewit Wongboonsin, David R Vanderwall, Tze Y Lim, Dominick Santoriello, Yask Gupta, Michelle T McNulty, Satoshi Koyama, Sidhant Puntambekar, Andrew S Bomback und 33 weitere

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.1452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Elena Martinelli und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Apolipoprotein L1, Glomerulosclerosis, Focal Segmental, Renal Insufficiency, Chronic, Nephrotic Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The APOL1 M1 (p.N264K) variant protects against G2-associated APOL1 focal segmental glomerulosclerosis (FSGS) and chronic kidney disease (CKD). However, the utility of knowing an individual’s M1 status in guiding kidney disease diagnosis and other clinical scenarios remains underexplored.

Objective

To test 2 hypotheses: (1) in patients with APOL1 high-risk (HR) genotype kidney disease with at least 1 G2 allele, M1 can distinguish APOL1 CKD from non- APOL1 CKD; (2) in people with APOL1 low-risk (LR) genotypes, M1 is independently associated with protection against FSGS and CKD. Design, Setting, and Participants Retrospective case-control study using data from 2 tertiary care hospitals (Columbia University Irving Medical Center and Mass General Brigham Biobank) and population-based data (the UK Biobank [UKB], Electronic Medical Records and Genomics [eMERGE-III], and All of Us [AoU]). Participants were individuals with a diagnosis of FSGS or steroid-resistant nephrotic syndrome (SRNS), individuals with CKD, and controls. Exposures Exposures included the M1 variant (p.N264K) obtained from exome or genome sequencing data, sex, and genetic ancestry. Main outcome and measure The main outcome was the presence or absence of kidney disease, defined as FSGS or non-FSGS CKD, compared with non–kidney disease controls. Association between the M1 variant and disease status was assessed using odds ratios (ORs).

Results

A total of 107 696 individuals (54 994 [51.1%] female; 8779 [8.2%] with African ancestry, 78 475 [72.9%] with European ancestry, and 16 129 [15.0%] with multiethnic ancestry), including 3460 with FSGS or SRNS, 24 382 with non-FSGS CKD kidney disease, and 79 854 controls were enrolled in the discovery cohort. In the APOL1 -HR group (1413 participants), M1 was significantly inversely associated with FSGS or SRNS cases compared with controls without kidney disease (OR, 0.20; 95% CI, 0.04-0.63; P = 3.69 × 10 −3 ). Among individuals with CKD with APOL1 -HR genotypes, M1 was 4 times more frequent in those whose CKD was not due to FSGS or SRNS. Importantly, electronic health record and biopsy review identified an alternative, non- APOL1 cause for CKD in nearly all APOL1 -HR-M1 cases. There was no association between individuals with APOL1 -LR genotypes with M1 and protection against CKD or FSGS. Conclusions and relevance In this case-control study of 107 696 individuals, presence of an APOL1 -HR genotype M1 was significantly associated with protection against kidney disease, suggesting that it may have a role as a genetic modifier. Patients with CKD with an A POL1 -HR genotype and M1 should be evaluated for an alternative and potentially treatable cause of their CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein L1Glomerulosclerosis, Focal SegmentalRenal Insufficiency, ChronicNephrotic SyndromeHumansFemaleMaleCase-Control StudiesRetrospective StudiesMiddle AgedAdultGenetic Predisposition to DiseaseGenotype

Substanzen

Apolipoprotein L1APOL1 protein, human

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
  • Division of Pediatric Nephrology, Boston Children's Hospital, Boston, Massachusetts.
  • Renal Division, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Nephrology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Bumrungrad Genomic Medicine Institute and Department of Medicine, Bumrungrad International Hospital, Bangkok, Thailand.

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Martinelli, E., Ke, J., Khan, A., Wongboonsin, J., Vanderwall, D. R., Lim, T. Y., Santoriello, D., Gupta, Y., McNulty, M. T., Koyama, S., Puntambekar, S., Bomback, A. S., Canetta, P., Kretzler, M., Montini, G., Morello, W., Maggiore, U., Fiaccadori, E., Gesualdo, L., …, & Columbia Genomics Consortium (2026). Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.1452

Vancouver

Martinelli E, Ke J, Khan A, Wongboonsin J, Vanderwall DR, Lim TY, et al. Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.1452

BibTeX
@article{Martinelli2026,
  author = {Martinelli, Elena and Ke, Juntao and Khan, Atlas and Wongboonsin, Janewit and Vanderwall, David R and Lim, Tze Y and Santoriello, Dominick and Gupta, Yask and McNulty, Michelle T and Koyama, Satoshi and Puntambekar, Sidhant and Bomback, Andrew S and Canetta, Pietro and Kretzler, Matthias and Montini, Giovanni and Morello, William and Maggiore, Umberto and Fiaccadori, Enrico and Gesualdo, Loreto and Ghiggeri, Gian Marco and Oliveira, Eduardo Araújo and Simoes E Silva, Ana Cristina and Bendapudi, Pavan K and Motelow, Joshua and Garcia, Christine K and Paul, Dirk S and Petrovski, Slavé and Goldstein, David B and Friedman, David J and Radhakrishnan, Jai and Lin, Fangming and Mohan, Sumit and Appel, Gerald B and Saleem, Moin A and Natarajan, Pradeep and Hildebrandt, Friedhelm and Westland, Rik and D'Agati, Vivette D and Gbadegesin, Rasheed and Gharavi, Ali G and Pollak, Martin R and Kiryluk, Krzysztof and Sampson, Matthew G and Sanna-Cherchi, Simone and Columbia Genomics Consortium, Columbia Genomics Consortium},
  title = {Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.1452}
}
Kostenlos starten →